Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants.
We recently found that estrogen deficiency leads to a lowering of thiol antioxidant defenses in rodent bone. Moreover, administration of agents that increase the concentration in bone of glutathione, the main intracellular antioxidant, prevented estrogen-deficiency bone loss, whereas depletion of glutathione by buthionine sulfoximine (BSO) administration provoked substantial bone loss. It has been shown that the estrogen-deficiency bone loss is dependent on TNFalpha signaling. Therefore, a model in which estrogen deficiency causes bone loss by lowering antioxidant defenses predicts that the osteopenia caused by lowering antioxidant defenses should similarly depend on TNFalpha signaling. We found that the loss of bone caused by either BSO administration or ovariectomy was inhibited by administration of soluble TNFalpha receptors and abrogated in mice deleted for TNFalpha gene expression. In both circumstances, lack of TNFalpha signaling prevented the increase in bone resorption and the deficit in bone formation that otherwise occurred. Thus, depletion of thiol antioxidants by BSO, like ovariectomy, causes bone loss through TNFalpha signaling. Furthermore, in ovariectomized mice treated with soluble TNFalpha receptors, thiol antioxidant defenses in bone remained low, despite inhibition of bone loss. This suggests that the low levels of antioxidants in bone seen after ovariectomy are the cause, rather than the effect, of the increased resorption. These experiments are consistent with a model for estrogen-deficiency bone loss in which estrogen deficiency lowers thiol antioxidant defenses in bone cells, thereby increasing reactive oxygen species levels, which in turn induce expression of TNFalpha, which causes loss of bone.
Jagger
C J
CJ
Department of Cellular Pathology, St. George's Hospital Medical School, London SW17 0RE, United Kingdom.
Lean
J M
JM
Davies
J T
JT
Chambers
T J
TJ
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D000975:Antioxidants / Q000378:metabolism*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control; D001862:Bone Resorption; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D004967:Estrogens / Q000172:deficiency; D005978:Glutathione / Q000172:deficiency*; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D010012:Osteogenesis; D010052:Ovariectomy; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction; D012995:Solubility; D013438:Sulfhydryl Compounds / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000963:Antimetabolites; D000975:Antioxidants; D004967:Estrogens; D018124:Receptors, Tumor Necrosis Factor; D013438:Sulfhydryl Compounds; D014409:Tumor Necrosis Factor-alpha; D019328:Buthionine Sulfoximine; D005978:Glutathione